Clene to Participate in the Maxim Group Virtual Healthcare Conference
Get Alerts CLNN Hot Sheet
Join SI Premium – FREE
SALT LAKE CITY, June 15, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, today announced that Rob Etherington, Chief Executive Officer, will participate in a fireside chat with Naz Rahman, Senior Biotech Research Analyst, at the Maxim Group Virtual Healthcare Conference on June 22, 2023 at 1:00 PM ET.
This conference will be live on M-Vest. To attend, click here: Healthcare Virtual Conference | M-Vest.
About Clene
Clene is a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease by targeting energetic failure, an underlying cause of many neurological diseases. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on Twitter, LinkedIn and Facebook.
| Contacts: | |
| Media Contact | Investor Contact |
| Ignacio Guerrero-Ros, Ph.D., or David Schull | Kevin Gardner |
| Russo Partners, LLC | LifeSci Advisors |
| [email protected] | [email protected] |
| [email protected] | 617-283-2856 |
| (858) 717-2310 |
Source: Clene Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Crypto News on Pepeto Second Exchange Debut, And The $2,775 BNB Price Prediction Every Holder Should Know
- Himax Technologies, Inc. Reports Second Quarter 2026 Financial Results; Provides Third Quarter 2026 Guidance
- DEMIRE Deutsche Mittelstand Real Estate AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Twitter, Maxim GroupSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share